China is tightening export controls on fentanyl precursor chemicals being shipped to North America — as China and the U.S. continue to make progress toward ending months of trade turbulence between the two nations. According to The New York Times, China’s Ministry of Commerce is requiring manufacturers to obtain a license to export 13 separate chemicals to the U.S., Mexico, and Canada. Among these chemicals are several precursors used to synthesize fentanyl, the opioid that has triggered a sharp rise in overdose deaths across the U.S. for years. The Centers for Disease Control and Prevention (CDC) estimates fentanyl killed more than 48,000 people in 2024 — compared to more than 76,000 in the prior year. From a supply chain perspective, fentanyl, as a synthetic opioid, is 50-100 times more potent than morphine and 50 times more potent than heroin — making it the primary driver of the deadliest drug crisis in the past decade globally.
The Trump administration has long criticized China for failing to adequately address illicit shipments of fentanyl precursors to the U.S. President Donald Trump has also identified the fentanyl crisis as one of the primary motivations behind the heavy tariffs being imposed on Chinese imports. From a supply chain perspective, Trump 2.0 imposed a 20 percent “fentanyl tariff” on China under IEEPA in February 2025 — and a 25 percent fentanyl tariff on Mexico and Canada. The U.S. accounts for more than 75 percent of global fentanyl deaths — with primary entry routes being the U.S.-Mexico border (cartel production in Sinaloa and Jalisco New Generation), the U.S.-Canada border, and direct mail shipments from China. The U.S. DEA (Drug Enforcement Administration), CBP (Customs and Border Protection), HSI (Homeland Security Investigations), ICE (Immigration and Customs Enforcement), FBI, and USPS (U.S. Postal Service) are the primary agencies combating fentanyl.
From a supply chain perspective, the fentanyl supply chain comprises China precursor chemicals (NPP, 4-ANPP, 4-piperidone, norfentanyl, 1-boc-4-anilinopiperidine), Mexico cartel synthesis (Sinaloa Cartel, Jalisco New Generation Cartel / CJNG), U.S. distribution (street gang networks), and fatal use (fentanyl-laced heroin, counterfeit pills, xylazine combo “tranq”) as the main pipeline. The UNODC (United Nations Office on Drugs and Crime) and INCB (International Narcotics Control Board) are the regulatory bodies for global narcotics control. The CCC (Counter Narcotics Working Group) is the bilateral cooperation framework between the U.S. and China — launched at the Biden-Xi APEC San Francisco summit in November 2023. The Trump-Xi APEC South Korea summit in October 2025 marks a new phase of trade-fentanyl negotiations. Scheduling, controlled substance, precursor chemical, and analog are the key terms in drug control legislation.
From a supply chain perspective, the global pharmaceutical and chemical supply chain comprises API (Active Pharmaceutical Ingredient), intermediate, excipient, and finished dosage form as the main production stages. China produces more than 40 percent of global APIs and pharmaceutical intermediates. Sinopharm, WuXi AppTec, WuXi Biologics, Hisun Pharmaceutical, Hengrui Medicine, Yangtze River Pharmaceutical, and the Beijing-Tianjin-Hebei, Yangtze River Delta, and Pearl River Delta regions represent China’s major pharmaceutical clusters and players. Pfizer, Johnson & Johnson, Roche, Novartis, Merck, AbbVie, AstraZeneca, GSK, Sanofi, Eli Lilly, and Bristol Myers Squibb are the global Big Pharma players. The U.S. BIOSECURE Act is legislation that restricts the U.S. from doing business with Chinese biotechnology companies (WuXi, BGI). In conclusion, China’s move to place 13 fentanyl precursors under a licensing regime represents a significant win in the U.S.-China “trade-narcotics” negotiations.
Key Points:
1. China is mandating export licenses for 13 fentanyl precursor chemicals.
2. The U.S., Mexico, and Canada are the licensing requirement destinations.
3. The CDC reports 2024 fentanyl deaths at 48,000+, and 2023 at 76,000+.
4. Trump is identifying fentanyl as a primary motivation for China tariffs.
5. U.S.-China trade turbulence is signaling progress toward resolution.
